Ignite Creation Date:
2025-12-24 @ 7:02 PM
Ignite Modification Date:
2026-01-14 @ 8:01 AM
Study NCT ID:
NCT02555657
Status:
COMPLETED
Last Update Posted:
2021-12-10
First Post:
2015-09-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-10-13
Start Date Type:
ACTUAL
Primary Completion Date:
2019-04-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-11-10
Completion Date Type:
ACTUAL
First Submit Date:
2015-09-18
First Submit QC Date:
None
Study First Post Date:
2015-09-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-03-27
Results First Submit QC Date:
None
Results First Post Date:
2020-05-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-11-09
Last Update Post Date:
2021-12-10
Last Update Post Date Type:
ACTUAL